OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

HTML

Year: 2010
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-09-3368
Authors: Alain C. Mita, Chris H. Takimoto, Monica Mita, Anthony Tolcher, Kamalesh Sankhala, John Sarantopoulos, Manuel Valdivieso, Leslie Wood, Erik Rasmussen, Yu-Nien Sun, Z. Don Zhong, Michael B. Bass, NgocDiep Le, Patricia LoRusso
Institutions: Amgen (United States), The Barbara Ann Karmanos Cancer Institute, Wayne State University
Language: English

Topic: Angiogenesis and VEGF in Cancer
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: peptibody, advanced solid tumors, FOLFOX4, carboplatin-paclitaxel, docetaxel, combination chemotherapy, anticancer activity, safety and tolerability, pharmacokinetics, pharmacokinetic interactions, bladder cancer, tumor response
SDG: Good health and well-being

Open Access status: closed

Funder: Amgen
OpenAlex ID: W2132827381
FWCI: 4.7
Cites: 24
Cited by: 107
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security